<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01627886</url>
  </required_header>
  <id_info>
    <org_study_id>BA0859144-01</org_study_id>
    <nct_id>NCT01627886</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition</brief_title>
  <official_title>Open-Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two-Period, Single-Dose, Crossover Oral Bioequivalence Study Of Ibandronate Sodium 150 mg Tablets Of Dr. Reddy's Laboratories Limited, India and 'BONIVA®' 150 mg (Ibandronate Sodium) Tablets Of Roche Laboratories Inc., USA In Healthy, Adult, Human Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, randomised, balanced, two-treatment, two-period, two-sequence,&#xD;
      crossover, oral bioequivalence study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two-Period, Single-Dose,&#xD;
      Crossover Oral Bioequivalence Study Of Ibandronate Sodium 150 mg Tablets Of Dr. Reddy's&#xD;
      Laboratories Limited, India And 'BONIVA®' 150 mg (Ibandronate Sodium)Tablets Of Roche&#xD;
      Laboratories Inc., USA In Healthy, Adult, Human Subjects Under Fasting Conditions (With As&#xD;
      Many Postmenopausal Women As Possible).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve(AUC)</measure>
    <time_frame>Prior to dosing (0.0 hour) and at 0.25, 0.50, 0.75, 1.0, 1.25, 1.50, 2.0, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 24.0, 36.0, 48.0 and 72.0 hours post dose.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ibandronate sodium tablets 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibandronate sodium tablets 150 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boniva</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Boniva Tablets 150 mg of Roche Laboratories Inc, USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibandronate sodium</intervention_name>
    <description>Ibandronate sodium Tablets 150 mg</description>
    <arm_group_label>Boniva</arm_group_label>
    <arm_group_label>Ibandronate sodium tablets 150 mg</arm_group_label>
    <other_name>Boniva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subjects should be healthy human of 18 years or older.&#xD;
&#xD;
          2. The subjects should be screened within 21 days prior to the administration of first&#xD;
             dose of the study drug.&#xD;
&#xD;
          3. The subjects should have a BMI between 19 and 30 weight in kg/ height2 in meter.&#xD;
&#xD;
          4. The subjects should be able to communicate effectively with study personnel.&#xD;
&#xD;
          5. The subjects should be able to give written informed consent to participate in the&#xD;
             study.&#xD;
&#xD;
             If subject is a female volunteer and&#xD;
&#xD;
          6. Is of child bearing potential practicing an acceptable method of birth control for the&#xD;
             duration of the study as judged by the investigator(s), such as condoms,foams,&#xD;
             jellies, diaphragm, intrauterine device (IUD), or abstinence or&#xD;
&#xD;
          7. Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
             hysterectomy has been performed on the subject) or&#xD;
&#xD;
          8. Should be postmenopausal healthy women who have attained complete menopause and have&#xD;
             not had menstruation for at least one year and are not on hormone replacement therapy.&#xD;
&#xD;
          9. Should have 17ß-estradiol serum levels of ≤92 pmol/L, follicle stimulating hormone&#xD;
             (FSH) of ≥40 IU/L during the screening (only for postmenopausal healthy women)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subjects who have a history of allergic responses to Ibandronate or other related&#xD;
             drugs.&#xD;
&#xD;
          2. The subjects who have significant diseases or clinically significant abnormal findings&#xD;
             during screening [medical history, physical examination, laboratory evaluations, ECG,&#xD;
             X-ray and vaginal ultrasonography recordings (only for female subjects)]&#xD;
&#xD;
          3. The subjects who have any disease or condition which might compromise the&#xD;
             haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central&#xD;
             nervous system, diabetes, psychosis or any other body system.&#xD;
&#xD;
          4. The subjects who have a history or presence of bronchial asthma.&#xD;
&#xD;
          5. The subject who have used enzyme-modifying drugs within 30 days prior to receiving the&#xD;
             first dose of study medication.&#xD;
&#xD;
          6. The subjects who have history of drug dependence, recent history of alcoholism or of&#xD;
             moderate alcohol uses.&#xD;
&#xD;
          7. The subjects who are smokers who smoke more than or equal to 10 cigarettes per day or&#xD;
             more than or equal to 20 biddies per day or those who can not refrain from smoking&#xD;
             during study period.&#xD;
&#xD;
          8. The subjects with a history of difficulty with donating blood or difficulty in&#xD;
             accessibility of veins.&#xD;
&#xD;
          9. The subjects who have donated 1 unit (350 ml / 450 ml) blood within 90 days prior to&#xD;
             receiving the first dose of study medication.&#xD;
&#xD;
         10. The subjects who have a positive hepatitis screen (includes subtypes A, B, C &amp; E).&#xD;
&#xD;
         11. The subjects who have a positive test result for HIV antibody and / or syphilis&#xD;
             (RPR/VDRL).&#xD;
&#xD;
         12. The subject who receives an investigational product, or has participated in a drug&#xD;
             research study within a period of 90 days prior to the first dose of the study&#xD;
             medication administration.&#xD;
&#xD;
         13. Female volunteers demonstrating a positive pregnancy screen.&#xD;
&#xD;
         14. Female volunteers who are currently breast-feeding.&#xD;
&#xD;
         15. Female volunteers not willing to use contraception during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Simran Sethi, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>BA Research India Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BA Research India Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>June 22, 2012</study_first_submitted>
  <study_first_submitted_qc>June 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <last_update_submitted>June 27, 2012</last_update_submitted>
  <last_update_submitted_qc>June 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Ibandronate Sodium</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibandronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

